A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Several CSF and blood biomarkers for genetic frontotemporal dementia have been proposed, including those reflecting neuroaxonal loss (neurofilament light chain and phosphorylated neurofilament heavy chain), synapse dysfunction [neuronal pentraxin 2 (NPTX2)], astrogliosis (glial fibrillary acidic protein) and complement activation (C1q, C3b). Determining the sequence in which biomarkers become abnormal over the course of disease could facilitate disease staging and help identify mutation carriers with prodromal or early-stage frontotemporal dementia, which is especially important as pharmaceutical trials emerge. We aimed to model the sequence of biomarker abnormalities in presymptomatic and symptomatic genetic frontotemporal dementia using cross-sectional data from the Genetic Frontotemporal dementia Initiative (GENFI), a longitudinal cohort study. Two-hundred and seventy-five presymptomatic and 127 symptomatic carriers of mutations in GRN, C9orf72 or MAPT, as well as 247 non-carriers, were selected from the GENFI cohort based on availability of one or more of the aforementioned biomarkers. Nine presymptomatic carriers developed symptoms within 18 months of sample collection (‘converters’). Sequences of biomarker abnormalities were modelled for the entire group using discriminative event-based modelling (DEBM) and for each genetic subgroup using co-initialized DEBM. These models estimate probabilistic biomarker abnormalities in a data-driven way and do not rely on previous diagnostic information or biomarker cut-off points. Using cross-validation, subjects were subsequently assigned a disease stage based on their position along the disease progression timeline. CSF NPTX2 was the first biomarker to become abnormal, followed by blood and CSF neurofilament light chain, blood phosphorylated neurofilament heavy chain, blood glial fibrillary acidic protein and finally CSF C3b and C1q. Biomarker orderings did not differ significantly between genetic subgroups, but more uncertainty was noted in the C9orf72 and MAPT groups than for GRN. Estimated disease stages could distinguish symptomatic from presymptomatic carriers and non-carriers with areas under the curve of 0.84 (95% confidence interval 0.80–0.89) and 0.90 (0.86–0.94) respectively. The areas under the curve to distinguish converters from non-converting presymptomatic carriers was 0.85 (0.75–0.95). Our data-driven model of genetic frontotemporal dementia revealed that NPTX2 and neurofilament light chain are the earliest to change among the selected biomarkers. Further research should investigate their utility as candidate selection tools for pharmaceutical trials. The model’s ability to accurately estimate individual disease stages could improve patient stratification and track the efficacy of therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationBridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764
Self-citationLui, H., Zhang, J., Makinson, S. R., Cahill, M. K., Kelley, K. W., Huang, H.-Y., Shang, Y., Oldham, M. C., Martens, L. H., Gao, F., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.001 · Cited by 729 · cited 1×
“15,16 As of yet, it is unclear when these biomarkers become abnormal and what temporal relationship exists between them.”
Self-citationNeurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss
Petzold, A. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.015 · Cited by 688
Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review
Seelaar, H., Rohrer, J. D., Pijnenburg, Y. A. L., Fox, N. C., & van Swieten, J. C. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.212225 · Cited by 609 · cited 1×
“Frontotemporal dementia (FTD), a form of early-onset dementia characterized by prominent behavioural and/or language impairments, is frequently caused by autosomal dominant mutations in granulin (GRN), chromosome 9 open reading frame 72 (C9orf72) or microtubule-associated protein tau (MAPT).(1,2) Upcoming therapeutic…”
Self-citationYoung, A. L., Marinescu, R. V., Oxtoby, N. P., Bocchetta, M., Yong, K., Firth, N. C., Cash, D. M., Thomas, D. L., Dick, K. M., Cardoso, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05892-0 · Cited by 596
Self-citationRohrer, J. D., Nicholas, J. M., Cash, D. M., van Swieten, J., Dopper, E., Jiskoot, L., van Minkelen, R., Rombouts, S. A., Cardoso, M. J., Clegg, S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70324-2 · Cited by 538
Self-citationNPTX2 and cognitive dysfunction in Alzheimer’s Disease
Xiao, M.-F., Xu, D., Craig, M. T., Pelkey, K. A., Chien, C.-C., Shi, Y., Zhang, J., Resnick, S., Pletnikova, O., Salmon, D., et al. (2017) · eLife · doi:10.7554/elife.23798 · Cited by 316
Moore, K. M., Nicholas, J., Grossman, M., McMillan, C. T., Irwin, D. J., Massimo, L., Van Deerlin, V. M., Warren, J. D., Fox, N. C., Rossor, M. N., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30394-1 · Cited by 313 · cited 1×
“In contrast to genetic Alzheimer’s disease, disease onset in FTD mutation carriers cannot be predicted based on familial onset age, 3 highlighting the need for biomarkers that can identify early disease activity.”
Self-citationA data-driven model of biomarker changes in sporadic Alzheimer’s disease
Young, A. L., Oxtoby, N. P., Daga, P., Cash, D. M., Fox, N. C., Ourselin, S., Schott, J. M., & Alexander, D. C. (2014) · Brain · doi:10.1093/brain/awu176 · Cited by 308
Self-citation
Research works printed but not linked: 36
- Lashley, 2015, Review: An update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations, Neuropathol Appl Neurobiol, 41, 858, 10.1111/nan.12250 · DOI · Paper page
- Desmarais, 2019, Therapeutic trial design for frontotemporal dementia and related disorders, J Neurol Neurosurg Psychiatry, 90, 412, 10.1136/jnnp-2018-318603 · DOI · Paper page
- Wilke, 2019, Correlations between serum and CSF pNfH levels in ALS, FTD and controls: A comparison of three analytical approaches, Clin Chem Lab Med, 57, 1556, 10.1515/cclm-2019-0015 · DOI · Paper page
- Rohrer, 2016, Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia, Neurology, 87, 1329, 10.1212/WNL.0000000000003154 · DOI · Paper page
- Eng, 1994, GFAP and astrogliosis, Brain Pathol, 4, 229, 10.1111/j.1750-3639.1994.tb00838.x · DOI · Paper page
- Rutkowski, 2010, Complement and the central nervous system: Emerging roles in development, protection and regeneration, Immunol Cell Biol, 88, 781, 10.1038/icb.2010.48 · DOI
- Venkatraghavan, 2019, Disease progression timeline estimation for Alzheimer's disease using discriminative event based modeling, Neuroimage, 186, 518, 10.1016/j.neuroimage.2018.11.024 · DOI · Paper page
- Panman, 2021, Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia, J Neurol Neurosurg Psychiatry, 92, 494, 10.1136/jnnp-2020-323541 · DOI · Paper page
- Oxtoby, 2018, Data-driven models of dominantly-inherited Alzheimer's disease progression, Brain, 141, 1529, 10.1093/brain/awy050 · doi:10.1093/brain/awy050
- Archetti, 2019, Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease, Neuroimage Clin, 24, 101954, 10.1016/j.nicl.2019.101954 · DOI · Paper page
- Venkatraghavan, 2021, Analyzing the effect of APOE on Alzheimer's disease progression using an event-based model for stratified populations, Neuroimage, 227, 117646, 10.1016/j.neuroimage.2020.117646 · DOI
- Oxtoby, 2021, Sequence of clinical and neurodegeneration events in Parkinson's disease progression, Brain, 144, 975, 10.1093/brain/awaa461 · DOI · Paper page
- Gabel, 2020, Evolution of white matter damage in amyotrophic lateral sclerosis, Ann Clin Transl Neurol, 7, 722, 10.1002/acn3.51035 · DOI
- Dekker, 2021, The sequence of structural, functional and cognitive changes in multiple sclerosis, Neuroimage Clin, 29, 102550, 10.1016/j.nicl.2020.102550 · DOI
- Preische, 2019, Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease, Nat Med, 25, 277, 10.1038/s41591-018-0304-3 · DOI · Paper page
- Benatar, 2019, Neurofilaments in pre-symptomatic ALS and the impact of genotype, Amyotroph Lateral Scler Frontotemporal Degener, 20, 538, 10.1080/21678421.2019.1646769 · DOI · Paper page
- Gorno-Tempini, 2011, Classification of primary progressive aphasia and its variants, Neurology, 76, 1006, 10.1212/WNL.0b013e31821103e6 · DOI · Paper page
- Malone, 2015, Accurate automatic estimation of total intracranial volume: A nuisance variable with less nuisance, Neuroimage, 104, 366, 10.1016/j.neuroimage.2014.09.034 · DOI · Paper page
- Ling, 2018, Synaptic paths to neurodegeneration: The emerging role of TDP-43 and FUS in synaptic functions, Neural Plast, 2018, 8413496, 10.1155/2018/8413496 · DOI · Paper page
- Marttinen, 2015, Synaptic dysfunction and septin protein family members in neurodegenerative diseases, Mol Neurodegener, 10, 16, 10.1186/s13024-015-0013-z · DOI · Paper page
- Terry, 1991, Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment, Ann Neurol, 30, 572, 10.1002/ana.410300410 · DOI · Paper page
- Petzold, 2009, Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy, J Neurol Sci, 279, 76, 10.1016/j.jns.2008.12.037 · DOI
- Zucchi, 2018, A motor neuron strategy to save time and energy in neurodegeneration: Adaptive protein stoichiometry, J Neurochem, 146, 631, 10.1111/jnc.14542 · DOI
- Kušnierová, 2019, Neurofilament levels in patients with neurological diseases: A comparison of neurofilament light and heavy chain levels, J Clin Lab Anal, 33, e22948, 10.1002/jcla.22948 · DOI
- Benatar, 2020, Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS, Neurology, 95, e59, 10.1212/WNL.0000000000009559 · DOI · Paper page
- Lu, 2015, Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: Insights from a longitudinal study, J Neurol Neurosurg Psychiatry, 86, 565, 10.1136/jnnp-2014-307672 · DOI · Paper page
- Adiutori, 2018, The proteome of neurofilament-containing protein aggregates in blood, Biochem Biophys Rep, 14, 168
- Lu, 2011, A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament "hook" effect, J Neurosci Methods, 195, 143, 10.1016/j.jneumeth.2010.11.026 · DOI
- Petzold, 2003, A specific ELISA for measuring neurofilament heavy chain phosphoforms, J Immunol Methods, 278, 179, 10.1016/S0022-1759(03)00189-3 · DOI · Paper page
- Jiskoot, 2016, Presymptomatic cognitive decline in familial frontotemporal dementia: A longitudinal study, Neurology, 87, 384, 10.1212/WNL.0000000000002895 · DOI · Paper page
- Jiskoot, 2018, Longitudinal cognitive biomarkers predicting symptom onset in presymptomatic frontotemporal dementia, J Neurol, 265, 1381, 10.1007/s00415-018-8850-7 · DOI · Paper page
- Valente, 2019, Phenocopy syndrome of behavioral variant frontotemporal dementia: A systematic review, Alzheimers Res Ther, 11, 30, 10.1186/s13195-019-0483-2 · DOI · Paper page
- van der Ende, 2021, Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions, J Neurol Neurosurg Psychiatry, 92, 502, 10.1136/jnnp-2020-325377 · DOI
- Bertrand, 2018, Early cognitive, structural, and microstructural changes in presymptomatic C9orf72 carriers younger than 40 years, JAMA Neurol, 75, 236, 10.1001/jamaneurol.2017.4266 · DOI · Paper page
- Jiskoot, 2019, Longitudinal multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia, Brain, 142, 193, 10.1093/brain/awy288 · DOI · Paper page
- Oxtoby, 2017, Data-driven sequence of changes to anatomical brain connectivity in sporadic Alzheimer's disease, Front Neurol, 8, 580, 10.3389/fneur.2017.00580 · DOI · Paper page
Cited by
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Zheng, Q., & Wang, X. (2025) · Protein & Cell · doi:10.1093/procel/pwae026 · Cited by 410
Zhou, J., Wade, S. D., Graykowski, D., Xiao, M.-F., Zhao, B., Giannini, L. A. A., Hanson, J. E., van Swieten, J. C., Sheng, M., Worley, P. F., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf0141 · Cited by 152
Temporal order of clinical and biomarker changes in familial frontotemporal dementia
Staffaroni, A. M., Quintana, M., Wendelberger, B., Heuer, H. W., Russell, L. L., Cobigo, Y., Wolf, A., Goh, S.-Y. M., Petrucelli, L., Gendron, T. F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01942-9 · Cited by 140
Self-citationSynaptic Loss in Frontotemporal Dementia Revealed by [ 11 C ] UCB‐J Positron Emission Tomography
Malpetti, M., Jones, P. S., Cope, T. E., Holland, N., Naessens, M., Rouse, M. A., Rittman, T., Savulich, G., Whiteside, D. J., Street, D., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26543 · Cited by 53
“In particular, neuronal pentraxin 2 is described as the earliest biomarker to become detectably abnormal, as compared to other CSF markers, in presymptomatic carriers of gene mutations related to frontotemporal dementia.(44) However, these markers are largely restricted to CSF-based rather than blood-based assays.”
BackgroundSelf-citationBiomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis
Katzeff, J. S., Bright, F., Phan, K., Kril, J. J., Ittner, L. M., Kassiou, M., Hodges, J. R., Piguet, O., Kiernan, M. C., Halliday, G. M., et al. (2022) · Brain · doi:10.1093/brain/awac077 · Cited by 48
“Blood and CSF NfL is amongst the earliest markers to change in patients transitioning from presymptomatic to symptomatic.(79) Furthermore, NfL could be used to differentiate amyotrophic lateral sclerosis subtypes.”
Background
Metadata
- Authors
- van der Ende, E. L., Bron, E. E., Poos, J. M., Jiskoot, L. C., Panman, J. L., Papma, J. M., Meeter, L. H., Dopper, E. G. P., Wilke, C., Synofzik, M., Heller, C., Swift, I. J., Sogorb-Esteve, A., Bouzigues, A., Borroni, B., Sanchez-Valle, R., Moreno, F., Graff, C., Laforce, R., Galimberti, D., Masellis, M., Tartaglia, M. C., Finger, E., Vandenberghe, R., Rowe, J. B., de Mendonça, A., Tagliavini, F., Santana, I., Ducharme, S., Butler, C. R., Gerhard, A., Levin, J., Danek, A., Otto, M., Pijnenburg, Y. A. L., Sorbi, S., Zetterberg, H., Niessen, W. J., Rohrer, J. D., Klein, S., van Swieten, J. C., Venkatraghavan, V., Seelaar, H., GENFI consortium, Afonso, S., Almeida, M. R., Anderl-Straub, S., Andersson, C., Antonell, A., Archetti, S., Arighi, A., Balasa, M., Barandiaran, M., Bargalló, N., Bartha, R., Bender, B., Benussi, A., Benussi, L., Bessi, V., Binetti, G., Black, S., Bocchetta, M., Borrego-Ecija, S., Bras, J., Bruffaerts, R., Cañada, M., Cantoni, V., Caroppo, P., Cash, D., Castelo-Branco, M., Convery, R., Cope, T., Di Fede, G., Díez, A., Duro, D., Fenoglio, C., Ferrari, C., Ferreira, C. B., Fox, N., Freedman, M., Fumagalli, G., Gabilondo, A., Gasparotti, R., Gauthier, S., Gazzina, S., Giaccone, G., Gorostidi, A., Greaves, C., Guerreiro, R., Hoegen, T., Indakoetxea, B., Jelic, V., Karnath, H.-O., Keren, R., Langheinrich, T., Leitão, M. J., Lladó, A., Lombardi, G., Loosli, S., Maruta, C., Mead, S., Miltenberger, G., van Minkelen, R., Mitchell, S., Moore, K., Nacmias, B., Nicholas, J., Öijerstedt, L., Olives, J., Ourselin, S., Padovani, A., Peakman, G., Pievani, M., Pijnenburg, Y., Polito, C., Premi, E., Prioni, S., Prix, C., Rademakers, R., Redaelli, V., Rittman, T., Rogaeva, E., Rosa-Neto, P., Rossi, G., Rosser, M., Santiago, B., Scarpini, E., Schönecker, S., Semler, E., Shafei, R., Shoesmith, C., Tábuas-Pereira, M., Tainta, M., Taipa, R., Tang-Wai, D., Thomas, D. L., Thompson, P., Thonberg, H., Timberlake, C., Tiraboschi, P., Todd, E., Van Damme, P., Vandenbulcke, M., Veldsman, M., Verdelho, A., Villanua, J., Warren, J., Woollacott, I., Wlasich, E., & Zulaica, M.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-10-11
- Volume
- 145
- Issue
- 5
- Pages
- 1805-1817
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W3205797556
- Cited by
- 58
- References
- 28
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. https://app.cochat.ai/papers/10.1093/brain/awab382
- The paper
- van der Ende, E. L., Bron, E. E., Poos, J. M., Jiskoot, L. C., Panman, J. L., Papma, J. M., Meeter, L. H., Dopper, E. G. P., Wilke, C., Synofzik, M., Heller, C., Swift, I. J., Sogorb-Esteve, A., Bouzigues, A., Borroni, B., Sanchez-Valle, R., Moreno, F., Graff, C., Laforce, R., . . . Zulaica, M. (2022). A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain. https://doi.org/10.1093/brain/awab382
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.